These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20617576)

  • 1. Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.
    Hicks CB
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20617576
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).
    Molina JM; Levy Y; Fournier I; Hamonic S; Bentata M; Beck-Wirth G; Gougeon ML; Venet A; Madelaine I; Sereni D; Jeanblanc F; Boulet T; Simon F; Aboulker JP;
    J Infect Dis; 2009 Jul; 200(2):206-15. PubMed ID: 19508157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
    Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
    J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved treatment results with interleukin-2.
    HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.
    David D; Naït-Ighil L; Dupont B; Maral J; Gachot B; Thèze J
    J Infect Dis; 2001 Mar; 183(5):730-5. PubMed ID: 11181149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality analysis of HIV-1 infected patients for prioritizing antiretroviral drug therapy.
    Pathipvanich P; Rojanawiwat A; Ariyoshi K; Miura T; Pumpradit W; Wongchoosie S; Yingseree P; Warachit P; Sawanpanyalert P
    J Med Assoc Thai; 2004 Aug; 87(8):951-4. PubMed ID: 15471301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 2 and HIV RNA Levels.
    Go R; Steigbigel R
    Arch Intern Med; 2007 Oct; 167(19):2144-5; author reply 2145. PubMed ID: 17954814
    [No Abstract]   [Full Text] [Related]  

  • 9. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.
    Negredo E; Massanella M; Puig J; Pérez-Alvarez N; Gallego-Escuredo JM; Villarroya J; Villarroya F; Moltó J; Santos JR; Clotet B; Blanco J
    Clin Infect Dis; 2010 May; 50(9):1300-8. PubMed ID: 20367229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-2 plus HAART reduces HIV in immune system "hiding places".
    WORLD; 1998 Dec; (No 92):7. PubMed ID: 11365976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.
    Markowitz N; Bebchuk JD; Abrams DI;
    Clin Infect Dis; 2003 Oct; 37(8):e115-20. PubMed ID: 14523786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
    N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
    Rajasuriar R; Booth D; Solomon A; Chua K; Spelman T; Gouillou M; Schlub TE; Davenport M; Crowe S; Elliott J; Hoy J; Fairley C; Stewart G; Cameron P; Lewin SR
    J Infect Dis; 2010 Oct; 202(8):1254-64. PubMed ID: 20812848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 clinical trials.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():58. PubMed ID: 11367495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
    Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS
    Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 therapy provides no clinical benefit to HIV-infected patients on ART.
    Clin Infect Dis; 2009 Apr; 48(8):iii. PubMed ID: 19301459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.